In vitro susceptibility to imipenem/relebactam and comparators in a multicentre collection of mycobacterium abscessus complex isolates

Seoane-Estévez, Alejandro; Aja-Macaya, Pablo; García-Pose, Andrea; López-Roa, Paula; Ruedas-López, Alba; González-Galán, Verónica; Esteban, Jaime; Arca-Suárez, Jorge; Pampín, Martín; Beceiro Casas, Alejandro; Oviaño, Marina; Bou, Germán

Use this link to cite:

https://hdl.handle.net/2183/47280

In vitro susceptibility to imipenem/relebactam and comparators in a multicentre collection of mycobacterium abscessus complex isolates

Files

Seoane_InVitro_2025.pdf (694.5 KB)

Seoane_InVitro_2025_Suppl.zip (152.88 KB)

Identifiers

URI: https://hdl.handle.net/2183/47280

DOI: 10.3390/antibiotics14070682

Publication date

2025-07-05

Authors

Seoane-Estévez, Alejandro

Aja-Macaya, Pablo

García-Pose, Andrea

López-Roa, Paula

Ruedas-López, Alba

González-Galán, Verónica

Esteban, Jaime

Arca-Suárez, Jorge

Pampín, Martín

Beceiro Casas, Alejandro

Bibliographic citation

Seoane-Estévez A, Aja-Macaya P, Garcia-Pose A, López-Roa P, Ruedas-López A, Gonzalez-Galán V, Esteban J, Arca-Suárez J, Pampín M, Beceiro A, Oviaño M, Bou G. In vitro susceptibility to imipenem/relebactam and comparators in a multicentre collection of mycobacterium abscessus complex isolates. Antibiotics (Basel). 2025;14(7):682.

Abstract

[Abstract] Background and Objectives: Infections caused by non-tuberculous mycobacteria (NTM), including Mycobacterium abscessus complex (MABc), are increasing globally and are notoriously difficult to treat due to the intrinsic resistance of these bacteria to many common antibiotics. The aims of this study were to demonstrate the in vitro activity of imipenem/relebactam against MABc clinical isolates and to determine any in vitro synergism between imipenem/relebactam and other antimicrobials. Methods: A nationwide collection of 175 MABc clinical respiratory isolates obtained from 24 hospitals in Spain (August 2022–April 2023) was studied. Fifteen different antimicrobial agents were comprised, including imipenem/relebactam. MICs were determined according to CLSI criteria, and the synergism studies were performed with the selected clinical isolates. Results: Of the 175 isolates obtained, 110 were identified as M. abscessus subsp. abscessus (62.9%), 51 as M. abscessus subsp. massiliense (29.1%), and 14 as M. abscessus subsp. bolleti (8%). The antibiotics yielding the highest susceptibility rates were tigecycline, eravacycline, and omadacycline (100%); followed by imipenem/relebactam and clofazimine (97.6%); and finally amikacin (94.6%). Only four isolates were resistant to imipenem/relebactam, three of which were further characterized by WGS, revealing MABc mutations in BlaMab as well as D,D- and L,D-transpeptidades and mspA porin, which may play an important role in reduced susceptibility to imipenem/relebactam, even though none were previously described or associated with resistance to β-lactams. Conclusions: Our data demonstrate that relebactam improved the anti-MABc activity of imipenem, representing a β-lactam for the treatment of MABc infections. Furthermore, imipenem/relebactam demonstrated in vitro synergism with other anti-MABc treatments, thus supporting its use as part of dual regimens.